The Senate Finance Drug Pricing Hearing Debrief

Tuesday, February 26th saw the highly anticipated Drug Pricing Hearing, as CEOs from seven different leading pharmaceutical companies presented before the Senate Finance Committee. These witnesses represented AbbVie, AstraZeneca, Bristol-Myers Squibb Co, Johnson & Johnson, Merck, Pfizer, and Sanofi and were called in to explain their drug pricing policies, as lawmakers criticized the process.

What You Missed

Pharmaceutical executives acknowledged that their prices are high for many patients, but they highlighted the insurance industry, government, and middlemen, known as pharmacy benefit managers, as causative agents. They each also briefly acknowledged that they have some role to play in lowering drug prices and out-of-pocket costs, but they defended their industry by turning the spotlight on their multibillion-dollar investments in research. These executives explained that the list prices they set for drugs are not what they are actually paid by insurance companies or PBMs. Read a full summary of the hearing here.

Yes or No

Many of the questions asked during the hearing required simple ‘yes’ or ‘no’ answers, with further discussion prevented by the senators. These parts of the hearing were generally unproductive, as the healthcare system is a complex entity with many moving pieces. Yes or no questions simply do not allow for adequate explanation from the CEOs and Senators.

Tax Break

Companies were asked several times about the usage of their tax breaks from the last Congress. Some Senators wanted to prove a point- that the tax law was largely unhelpful to regular Americans- and others wanted to know how much of the tax break went to lowering actual drug list price. 

The Tax Cuts and Jobs Act of 2017 was approved by the House Ways and Means Committee on November 9, 2017 and was passed in December 2017 by the Republican-led Congress as the largest piece of tax reform in decades. The TCJA had a wide reach, including introducing a flat corporate tax rate of 21% to pharmacy businesses, a wide variety of credit and deductions, increased expensing, saving pharmaceutical companies billions. The Act also reduced tax rates for other businesses and individuals, simplified personal tax, and repealed the individual mandate of the Affordable Care Act.

Patent System

Some of the Senators (Cornyn-R, Texas) brought up the idea of reforming the patent system so that drug formulas cannot continue to be re-patented in a seemingly endless loop. Gonzalez discussed how patents on Humira (AbbVie), for instance, are not simply on the formula of the drug and how they license the formula of the drug so other companies can produce it as well. Currently, patents protect drugs from copycats for 20 years upon the invention of the drug. This timespan includes the time spent in FDA trials, a process that takes an average of 9 years. 

A patent is not the only option for drug producers though. For new drugs, exclusivity can be granted as a period of time in which a brand-name drug is protected from generic competition and is offered exclusive marketing rights. Exclusivity can vary from 6 months to 7 years with additional extension possibilities, and attaches upon the approval of the drug product. Patents and exclusivity may or may not run concurrently, but the exclusivity clause will not add additional time to the patent life. However, current patent law allows drug companies to file patent after patent to extend the life of their exclusivity, and generic drugs can be challenged in court. Litigation via these two channels can cause the production of generics to be delayed by years. Click to learn more about patents and exclusivity from the FDA.

Rebate Reform

Some of the presenting pharmaceutical executives stated that they support the administrative proposal for rebate reform, which would change the current system in which drug prices are set using secret rebates negotiated by PBMs. “The change would make those rebates illegal and force pharmacy benefit managers to instead negotiate discounts upfront so that people will get the discounts at the pharmacy counter even if they haven’t yet met their deductible.”


International Pricing Index

Many Senators, especially Cardin (D- Maryland) and Cassidy (R- Louisiana), brought up the International Pricing Index. The IPI was proposed by the administration at the end of last year. It aims to tie American drug prices with international prices by setting a Target Price driven by the international pricing index, in hopes to lower the amount Medicare, and patients, pay for drugs. According to the Centers for Medicare & Medicaid Services (CMS), “the IPI Model would test whether increasing competition for private-sector vendors to negotiate drug prices, and aligning Medicare payments for drugs with prices that are paid in foreign countries, improves beneficiary access and quality of care while reducing expenditures.” The IPI is projected to start in Spring 2020 and save American taxpayers and patients $17.2 billion over five years.

Wyden’s Pledge

Wyden (D- Oregon) wanted each pharmaceutical executive to pledge that if rebates were eliminated from the market, the savings would go towards lowering prices. The companies have ten days to send an answer to his office, and several of the executives stated that they would have no problem signing such a pledge.

The Takeaway

Follow up from this hearing is key and Grassley (R-Iowa) promised he would have additional hearings on this issue. Himself and Wyden (D-Oregon) have stated the companies would be asked to present again on Capital Hill for further hearings.

Are You A Passionate Diabetes Advocate? Join the DPAC Patient Advisory Board!

What is the DPAC Patient Advisory Board?

The DPAC Patient Advisory Board (PAB) is a diverse group of people from the diabetes community who support DPAC’s mission and further its goals. From identifying and weighing in on diabetes policy advocacy issues on a federal and state level to advising on educational training content, the Diabetes Patient Advocacy Coalition’s PAB plays an integral role in ensuring the diabetes patients’ voices are heard. These members will represent DPAC at policy meetings, testimonies, and events that need a personal diabetes perspective.  

DPAC was founded by patients in the diabetes community to ensure that there was a trusted voice that represented all 30.3 million American families impacted by diabetes in the United States.  It is important to DPAC that all facets of our community are represented, since people being personally invested in our voice is essential.  Drawing from all corners of our community, we seek parents, patients, and significant others from all types of diabetes. 

The diverse viewpoints from the DPAC PAB members will ensure that DPAC represents all voices of the diabetes community. The input from the PAB will help ensure that DPAC continues to be the foremost organization in the diabetes advocacy space.

A bunch of hands touching


How Can You Get Involved?

We’re looking for people to join the DPAC PAB now! You can apply by filling out a short application, which will ask for you to answer a few questions. Applications are open between now and March 27, 2019. 

In order to ensure transparency and promote DPAC as the trusted patient advocacy voice, there are a few requirements for being a PAB member. If selected, you will: 

  • Commit a minimum of 2-5 hours per month of your time
  • Represent the faces and voices of our community
  • Attend online PAB meetings monthly (will transition to bi-monthly once in working groups)
  • Attend a DPAC Policy Training Meeting in D.C. (costs are covered)
  • Promote, represent, and advocate for DPAC’s issues
  • Be willing to share your personal story – whether that be through a blog post for DPAC’s website, or other ways via social media
  • Work collaboratively with staff and other members on particular issues, both State and Federal
  • Be active in the PAB online group forum and be willing to add to group conversation
  • Participate in advanced advocacy training either online or in person
  • Be willing to engage and promote DPAC on social media
  • Have a willingness to participate as a speaker or on a webinar regarding a topic that you are familiar with
  • Be independent from conflicting diabetes advocacy messaging. No PAB member may be an employee/contractor of another diabetes non-profit, corporation, or movement that influences the diabetes community in any way to ensure there are no conflicts of interest
  • Be a registered voter in the United States.

See the DPAC Patient Advisory Board application for details on the requirements and apply today! (You can upload your resume, letters of recommendation, and a cover letter in the application.)

We know that as a strong community, we’ve already done so much.

Let’s make sure that our policy makers continue to hear from us!


PBMs: Who, What, and Why Change

Pharmacy Benefit Managers (PBMs) have been a particular topic of interest as of late. But, what is a PBM? And what makes them so important?

PBMs and You

These companies are third parties hired by insurance companies, private employers and government entities to manage drug benefit programs. Only originating a few decades ago, PBMs already have a large impact on health care decision making in the United States. As prescription drug coverage has expanded, so has the role of PBMs who now impact a majority of prescription drug transactions today. Originally founded to reduce prescription drug costs, improve convenience and safety, and protect Medicare patients, concerns have risen about what PBMs actually do.

According to PCMA, PBMs manage prescription drug plans for more than 266 million Americans and boast they project to save parties $654 billion. However, recent research has shown that PBMs have begun to negotiate discounts and rebates from pharmaceutical manufactures that they instead keep instead of passing on to patients. This results in patients paying amounts that may not actually reflect a lower drug cost.

Learn more about PBMs and how they work by watching the short video below from Kaiser Health. 

The transparency of Pharmacy Benefit Managers has been particularly questioned as of late. Since PBMs negotiate pricing, the pharmacy is unaware of the health plan’s payments, whilst the health plan is unaware of the amount the pharmacy is rebated for dispensing the medication. This allows for a ‘spread’ in pricing, acting as a source of revenue for PBMs.

PBMs and Diabetes

The American Diabetes Association estimates that diabetes, already the most expensive chronic illness in the USA, has a total cost of more than $327 billion per year, including $15 billion for insulin, and the price keeps increasing as additional price increases were introduced early this year. Almost every pharmaceutical company that rolled out a price increase in January 2019 cited that all, or the majority, of the price increase was being utilized for rebates to be paid to health plans or PBMs. This rise in cost indicates PBMs may have a particular goal to negotiate higher rebates instead of lower prescription drug costs, causing little to no savings to the consumer.

PBMs and New Legislation

Recent legislation has focused on reworking this rebate system. The Trump Administration has proposed regulations that would encourage lower prescription drug costs via incentives, and reduce out of pocket spending. The Department of Health and Human Services Secretary Alex Azar shares that the Trump Administration aims to end backdoor deals in the pharmaceutical industry, particularly through the rebate system. The recent proposal aims to provide a new level of transparency to pass discounts directly to patient consumers. Read the full proposal here.

As the voices of the diabetes community, we encourage you to share your thoughts on the proposal and the state of PBMs.

We encourage you to tweet your thoughts on the Trump Administration’s proposal and the proposed changes to the rebate system. Consider using hashtags like #PBM and #APF to connect with relevant threads of other’s opinions.

We’ve linked some strong resources for you throughout the article (and here!) to learn more about PBMs and the new proposal. The best way to inspire change is to become an educated informant, so take a moment to read!

With the House and Senate locked on partisan debates, it’s more important than ever to encourage bipartisan conversations on health care. Engage in informed conversations with your friends, family, and neighbors to learn about their opinions.

We look forward to hearing your thoughts on the progression of health care legislature as we work on safety, quality, and access with you: the patient.

Share on facebook
Share on google
Share on twitter
Share on linkedin

Oklahomans! Ask your representative to cosponsor and support H.B. 1130, which caps the copay amount for insulin at $100!

On February 4th, Representative Bennett proposed H.B. 1130, which amends 36 O.S. 2011, Section 6060.2 to impose a cap on the amount an insurer can charge for a copay on insulin. The bill has been referred to the Committee on Insurance.

Approximately 451,888 people in Oklahoma, or 14.3% of the adult population, have diabetes, and many of them rely on insulin to stay healthy. Insulin has become harder to access in this age of high copay requirements. According to the Commonwealth Fund, many studies have shown that even a $5 copayment generally does have the expected impact of lowering drug utilization. For some individuals relying on insulin, copayments can be astronomically high – $150, $200, or even $500 depending on their insurance plan. This is obviously much more than the $5 it takes to dissuade someone from buying their medicine.

“I hope Oklahoma passes this piece of legislation because it could change the future of our state,” says Brooke Baker, a DPAC Champion living in Oklahoma. “Maybe we could go up the ranks and leave being worst in the nation for diabetes and it’s complications.”

Capping the copayment for insulin at $100 would be a huge step forward in making insulin more accessible for Oklahomans. A lower copay amount would mean that more Oklahomans would be able to access insulin, and that in turn would mean that those people could avoid costly complications caused by a lack of insulin.

What can you do?

Want to help this bill move along? We’ve done the hard work for you! We’ve drafted a letter that you can send with just a few clicks, so don’t wait! Ask your representative to cosponsor and support H.B. 1130 today to make insulin more accessible for Oklahomans!

Click here to send a letter to your representative!

Kentuckians: Ask Your Legislature to Support H.B. 64

Ask Kentucky lawmakers to support H.B. 64, which would allow pharmacists to prescribe the appropriate amount of a medication to a person facing an emergency – like someone who drops their last bottle of insulin on a Friday night!

Not Having Insulin is Simply Not an Option

For the 531,646 people in Kentucky with diabetes, not having insulin is not an option. Currently, emergency insulin is given only in a standardized amount, their preset ’72 hour emergency supply.’ Yet, each patient’s insulin needs differ, and sometimes the current emergency supply is not enough.

H.B. 64 would allow pharmacists to dispense the appropriate amount of prescription medications to patients in an emergent situation who are unable to get a prescription from their healthcare provider. This would allow insulin to be administered in an appropriate amount without need for concern. For a person who needs insulin, the time from being a healthy person with diabetes to hospitalization or death can be less than 72 hours.

Unfortunately, emergencies, such as dropping a bottle of insulin after hours, are common and the need for preventative measures is important. Providing patients with the means to access their medication in urgent conditions improves their quality of life. A simple accident could put a diabetic’s health at risk, a situation currently unfixable by patient or pharmacist with the current emergent prescription rules.

Emergency Medication is Necessary for Maintaining Health

Regardless of the type of diabetes or the medication regimen, emergency access to medication for each individual is crucial for maintaining health. The financial burden of treating short- and long-term complications due to lack of access impacts insurance providers and the state’s healthcare budget. ER visits and hospitalizations that could be avoided with this bill will not only save money, but save lives.     

Take Action Now!

Patients MUST have access to emergency medication in an amount best suited for them. A patient who is given a preset ’72 hour emergency supply’ can be dangerously under-medicated and can face serious complications. Click below to send a letter to lawmakers in Kentucky to support H.B. 64 to give patients access to emergency medication

Write a Letter to Kentucky Lawmakers

Kentuckians: Share your opinion and send a letter to lawmakers in support of H.B. 64 and emergency prescriptions!
Advocacy Definition

Guest Blog: Erin Bubb on What Patients are Doing with DPAC

Out of all the organizations out there, why DPAC?

Most of us who have lived in this world realize that, in order to effect the greatest amount of change you start from the top-down. DPAC starts with those seated in positions that have the power to literally change the world of those living with Diabetes. DPAC strives to make Diabetes Advocacy simple, so that “regular people” can change their voice into action.

Recently, DPAC had a Policy Training Meeting (PTM) to equip those “regular people” and develop them into “Champions for the Cause.” Items covered were: Advocating using Social Media, Talking to the Press, Overview of Diabetes Legislation, Access to Affordable Insulin, Diabetes Self-Management Training (DSMT), Knowing the Facts, Advocating at the State level, and telling My Story.

As I sat in that hotel conference room, I had mixed emotions about what I, a mom of a T1D, from a small town in Michigan was doing with people who are doing “real adult things,” and have already done so much for the diabetes community. Then we were tasked with writing Our Story, the story of why we fight. 

The story that no one else can tell. The story that made us say “Hell Yes, I’ll Go,” when DPAC said come fight with us. My story is not more compelling than anyone else’s story; it is just being amended to have a better ending.

An ending where my son doesn’t feel afraid to sleep at night, where he can chase his dreams, where he doesn’t feel like an outcast, and where he won’t have to fight, every month, for the medication that he needs to live on this Earth. 

My Story, comes with boxing gloves, because this Momma Bear is ready to fight.

After the PTM, I felt more knowledgeable about the causes and how to use my voice. I felt more equipped to speak about the facts, and I felt empowered to bring the concerns of the Diabetes Community to The Hill. Now my fight has focus and I have a firm foundation of knowledge to stand on. I feel like, if I asked, every single member of DPAC would stand next to me in that little Michigan town and fight alongside me.

The saying from the Lorax comes to mind when I think about this amazing group of people, “Unless someone like you cares a whole awful lot, nothing is going to get better. It’s not.” We may not be power-houses in our communities, but we care! We care enough to say, there has to be a better way!


Erin hails from the great state of Michigan. She is a wife, mother, lover of music, nature, and Michigan football. Her son was diagnosed with Type 1 Diabetes at the age of five (2015). Since then, she has immersed herself in learning all she can about this disease and how it impacts individuals and families. 


Erin has heard so many heart-wrenching stories that scream for change in the diabetes community. She has a passion to make these stories known and affect change. Erin currently volunteers on the Patient Advisory Council at her local hospital and enjoys connecting patients, caregivers, providers, and staff to help make Diabetes care a positive experience for all involved. She is passionate about non-medical switching and providing support for the diabetes community.

In Virginia? Ask your Legislature to Support H.B. 2515/S.B. 1596, and Ban Accumulator Adjustment Programs!

Accumulator adjustment programs limit access to diabetes medications – many of which have no generic substitute – and devices by preventing manufacturer copay assistance contributions from counting towards a beneficiary’s deductible and maximum out-of-pocket spending limits. 

Without consumer notice, insurance plans have been implementing accumulator adjustment programs. This causes patients to unexpectedly encounter steep prescription drug and device cost sharing mid year.

AdobeStock_78447100 compressed
Sample Health Insurance Form

Copay Cards and Affordable Access

Copay cards are used by patients to affordably access their medications and, often, patient heavily rely on these to budget their healthcare expenses. Few cost-effective medication alternatives are available to diabetic patients, causing a particular necessity for copay cards. 51% of copay coupons are for drugs with no generic substitute, 12% of which have no close therapeutic substitute at all. People with diabetes spend approximately 2.3 times more on healthcare than people without diabetes, causing accumulator adjustment programs to be disproportionally unjust to the diabetic community. Recent research shows that patients with type 2 diabetes are more likely to adhere to treatment protocol with lower copayments. Copay cards offer a means of assistance to overcome the cost hurdle of diabetes and assist in medical compliance.

H.B. 2515/S.B. 1596 requires that any carrier issuing a health plan in the Commonwealth to include any amounts paid by the enrollee or paid on behalf of the enrollee by another person when calculating an enrollee’s overall contribution to any out-of-pocket maximum, deductible, copayment, coinsurance, or other cost-sharing requirement under the health plan. Simply put, H.B. 2515/S.B. 1596 assists patients in their health care cost management by including copay cards in their cost-sharing requirements.

Accumulator Adjustment Programs and Cost Increase

Partial Hospital Bill with Copay, Deductible and Coinsurance sections

In addition, H.B. 2515/S.B. 1596 alleviates financial burden by preventing unexpected changes to patient’s heath care plans. Accumulator adjustment programs currently increase patient cost-sharing and cause beneficiaries to be uninformed of such programs. This causes beneficiaries to be faced with high-unforeseen costs that they often are unable to afford.

Act Now!

Banning accumulator adjustment programs allows diabetes patients to affordably manage their healthcare through utilizing copay cards and preventing unforeseen changes in their health coverage plans. Click here to send a letter to Virginia lawmakers in support of H.B. 2515/S.B. 1596!

Guest Blog: Mike Ratrie- We Need Sails

We cannot change the wind, we can only adjust our sails.

Yes, it’s a cliché, but stay with me for a moment and we’ll see if I can bring it home.

The wind is this case is pretty obvious, right? Our continuous, but unwanted companion, Diabetes. Some days it blows hot, howling and horrible, others cold, crafty and conniving, but every single day it blows (unless it sucks, of course). Regardless of Type, Diabetes is with us every moment of every day.

Since there’s no getting away from this chronic wind, how do we manage, how can we live and thrive?

We Need Sails.

Sails can be used and adjusted to help us reach our goals. We also regularly have to evaluate whether or not the sails we are using are still up to the job. Sails that are constantly buffeted by the wind (and sun, and rain, and sleet, and snow) need to be changed, renewed, replaced.

Now you can use your imagination to think of all the real-life D-items that can be used for metaphorical sails. Insulins, syringes, pens, test strips, meters, D-pills, etc are what immediately come to my mind.

But what about D-parents, our HCPs (including some fabulous CDEs), the DOC? Sails, every one of them.

picture of clear test tubes

How about Health Care policy, regulations and laws? Yes, they too are sails for us to use.

So this last part is what brings me to write this post.

I’m not going to come up with a cure, or develop an artificial pancreas. I’m not going to create a fabulous D-blog – there are so many great ones out there already.

But what I can do is use my voice with my legislators and policy makers, I can ask them to create better sails, or perhaps a better environment for others to create better sails – ones that can be adjusted more effectively. I can ask you to join me in raising our voices.

Being a DPAC Champion

To that end, I have been given the opportunity to be a part of the Diabetes Advocacy Patient Coalition, or DPAC, as a DPAC Champion. The final weekend in September and the very first day of October, the inaugural group of Champions went to Washington, DC to expand on DPAC’s mission to build better sails legislatively.

This group of about 25 diverse individuals have made a commitment to advocate, advocate, advocate and get to know not only our legislators, but also the staff members that do much of the heavy lifting when it comes to drafting and passing(!) legislation.

Together, the DPAC Champions plan to grow the voice of PWDs in our Nation’s capital, Washington, DC, and also in our Nation’s Capitals, from Annapolis to Tallahassee, Indianapolis to Frankfort, Sacramento to Baton Rouge and beyond. We want our legislators to gain a better understanding of what we face, and how they can positively impact our lives. In addition, through partnerships with the Lions Club International, the Association of Black Cardiologists, DPAC Champions hope to engage and energize everyone including “sugar-normals” to help advance legislative solutions to giving us better sails.

I’d love to hear from you as we “adjust our sails” in 2019.

About Mike

Diagnosed with Type 1 Diabetes in 1973, at age 19, Mike has led what can only be called an extremely normal life with variations. Married to Lucia Ratrie in 2014, Mike is a husband and father to a grown daughter, Anna, father in-law to her husband John, grandfather to two boys, Connor and Finn, step-dad to Lucia’s four grown children, Jason, Steven, Chad and Heather, and servant to 3 cats and 1 dog.

His ever-ready smile, silly humor and positivity have been a part of numerous adventures. These include 5 years on his own sailboat, ranging from Maine to Aruba, pedaling just under 6,000 miles with Lucia on an unsupported cross-country bike trip, and a second 2,000 mile trip from Vancouver Island, BC to Los Angeles, CA. 

A non-blogging member of the DOC since 2008, Mike started insulin pumping in 1999 and CGM’ing in late 2014. Mike is looking forward to moving beyond raising awareness to creating actions that lead to change.

Guest Post: Emma Zgonc on Developing Her Advocacy Story

I was diagnosed with type 1 diabetes in 2011 at age 12. After going to a doctor’s appointment where I was promised there would be no shots, I was ironically rushed to the hospital for a diagnosis of type 1 diabetes and shots for the rest of my life. Since then, I have had many ups and downs, but I have also found a community.

Her Community

I have been incredibly blessed with a wonderful and supportive family. Friends stood by me during my diagnosis and many of them learned with me as to how to best take care of myself. Having this supportive network by my side, I have always had someone there to advocate for me, whether it be with insurance, at a doctor’s office, or at school.

Now that I am older and have taken a primary role regarding my care, I have realized that I can do more advocacy for both myself and the diabetes community as a whole. I have always seen advocacy as something unreachable to a college student like me, but I have come to realize advocacy comes in many forms. While I may not be advocating every day on a federal or state level, anytime I educate others or demand the care I need in a school or healthcare setting, I am advocating for myself and others with diabetes.

The DPAC Policy Training Meeting

I had the opportunity to attend the very first Diabetes Patient Advocacy Coalition (DPAC) Policy Training meeting, along with more than 30 advocates from across the country. When I first found out I had the chance to go, I was immediately intimidated, as many of the attendees have years of experience with advocacy in either their personal or professional life. Upon arrival, I quickly realized that age and experience did not matter and that I had my own unique story to share. What stuck with me the most over the weekend was learning how to develop “my story”. My story of living with diabetes is completely my own. No one can discount my own experience, which made me realize that I had no reason to be nervous.

Emma Zgonc on Capital Hill

Saturday and Sunday were spent learning about policy issues that impact the diabetes community, social media, public speaker training, the ins-and-outs of a congressional office, along with many other ways to advocate. We learned about affordable insulin and the DSMT bill (HR 5768 and S 3366), the two issues we would later be advocating for with Congress on that Monday.

The Issues

In the past 15 years, the cost of insulin has nearly tripled. I have been fortunate to be able to afford insulin, but I know many are not and I often worry for when I have my own insurance. Currently, a month’s worth of insulin for me costs $1,200! This is a staggering amount, which causes many to be unable to afford it. I was so happy to have the opportunity to speak about the importance of insulin affordability on The Hill, but we need others to join this effort. Insulin affordability is a problem that impacts everyone with T1D and it is up to all of us to share our story in order to make change happen.

First DPAC Policy Training Meeting Attendees

I have always been on the quiet side and never thought I would be interested in a career in advocacy, but after attending the policy training meeting, I have found something that I am extremely passionate about! I have had so many loving people advocate for me, and it is now time for me to stand up and share my story and be a voice for those who can’t. I am excited to continue to advocate with DPAC on issues that matter to the diabetes community and share my experience with others who can help make a difference. You are never to old or young to advocate for change! My involvement with DPAC and the Policy Training meeting has given me the confidence to share my story.

About Emma

Emma Zgonc studies Sociology and is pursuing a Master of Global Health at Ohio University in Athens, OH. She will graduate in 2021. She was diagnosed with Type 1 diabetes at the age of 12. She is co-president of DOSES, OU’s CDN Chapter, a peer mentor for children with diabetes in the Athens area, and is a DPAC champion. She hopes to pursue a career in global health and advocate for those with diabetes and other chronic conditions worldwide.

Announcement: DPAC Policy Training Meeting Applications Are Now Being Accepted

DPAC is now accepting applications for the next DPAC Policy Training Meeting, which will take place in Washington, D.C. from April 30 to May 2, 2019. Individuals impacted by diabetes who have a passion for policy advocacy and wish to have advanced training are encouraged to apply.


DPAC held its first Policy Training meeting in October of 2018, which brought together advocates from all over the county.  This in-depth meeting will offer social media and public speaker training alongside education on policy issues our community currently faces and how to effectively advocate on a state and federal level. We’ll be bringing in experts and sharing best practices before we head up to Capitol Hill for Hill Day.

 Hill Day

Join your fellow DPAC advocates to meet with members of Congress and their staff, along with advocates from other organizations.  Rather than research funding (which is what JDRF and ADA do best, so why reinvent the wheel?!) meetings, this Hill Day’s focus will be on policy issues and upcoming bills in Congress. 

What’s Involved?

For those who have shown an interest in policy advocacy and are selected to attend, DPAC will provide travel and lodging to Washington, D.C. to attend the meeting. Tuesday and Wednesday will be intensive training days (sorry – no time to sightsee!). Thursday will be our Hill Day, and attendees will depart from the Hill to head back home.

What Comes Next?

The fun (and we hope it will be fun for attendees) doesn’t stop after the DPAC Policy Training Meeting. DPAC will be providing additional training and resources throughout 2019 to help these determined policy advocates in their own state. They may also be asked to speak in their state legislature (or come back to D.C.) on a diabetes issue. Diabetes policy advocacy isn’t a quick fix; we’re in this for the long-haul!

How Do I Apply?

Click here for the application.

Please take careful note of the application requirements and take your time answering the questions.

Applications will be accepted until FRIDAY, FEBRUARY 8th.


We will announce the DPAC Policy Training Meeting attendees the week of February 18th. 


We hope you’ll consider applying and joining us in Washington, D.C. to advocate for our community!

Skip to toolbar